Blockade of Electron Transport at the Onset of Reperfusion Decreases Cardiac Injury in Aged Hearts by Protecting the Inner Mitochondrial Membrane by Chen, Qun et al.
Virginia Commonwealth University
VCU Scholars Compass
Internal Medicine Publications Dept. of Internal Medicine
2012
Blockade of Electron Transport at the Onset of
Reperfusion Decreases Cardiac Injury in Aged
Hearts by Protecting the Inner Mitochondrial
Membrane
Qun Chen
Virginia Commonwealth University, qchen8@vcu.edu
Thomas Ross
Virginia Commonwealth University
Ying Hu
Virginia Commonwealth University, yhu@vcu.edu
Edward J. Lesnefsky
Virginia Commonwealth University, ejlesnefsky@vcu.edu
Follow this and additional works at: http://scholarscompass.vcu.edu/intmed_pubs
Copyright © 2012 Qun Chen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
This Article is brought to you for free and open access by the Dept. of Internal Medicine at VCU Scholars Compass. It has been accepted for inclusion
in Internal Medicine Publications by an authorized administrator of VCU Scholars Compass. For more information, please contact
libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/intmed_pubs/8
Hindawi Publishing Corporation
Journal of Aging Research
Volume 2012, Article ID 753949, 9 pages
doi:10.1155/2012/753949
Research Article
Blockade of Electron Transport at the Onset of
Reperfusion Decreases Cardiac Injury in Aged Hearts by
Protecting the Inner Mitochondrial Membrane
Qun Chen,1 Thomas Ross,1 Ying Hu,1 and Edward J. Lesnefsky1, 2, 3
1 Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University,
Richmond, VA 23298, USA
2 Department of Biochemistry, Virginia Commonwealth University, Richmond, VA 23298, USA
3 Cardiology Section, Medical Service 111 (J), McGuire VA Medical Center, Richmond, VA 23249, USA
Correspondence should be addressed to Edward J. Lesnefsky, ejlesnefsky@vcu.edu
Received 12 September 2011; Revised 23 November 2011; Accepted 27 December 2011
Academic Editor: Paula Bickford
Copyright © 2012 Qun Chen et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Myocardial injury is increased in the aged heart following ischemia-reperfusion (ISC-REP) compared to adult hearts. Intervention
at REP with ischemic postconditioning decreases injury in the adult heart by attenuatingmitochondrial driven cell injury. Unfortu-
nately, postconditioning is ineﬀective in aged hearts. Blockade of electron transport at the onset of REP with the reversible inhibitor
amobarbital (AMO) decreases injury in adult hearts. We tested if AMO treatment at REP protects the aged heart via preservation of
mitochondrial integrity. Buﬀer-perfused elderly Fischer 344 24mo. rat hearts underwent 25min global ISC and 30min REP. AMO
(2.5mM) or vehicle was given for 3min at the onset of REP. Subsarcolemmal (SSM) and interfibrillar (IFM) mitochondria were
isolated after REP. Oxidative phosphorylation (OXPHOS) and mitochondrial inner membrane potential were measured. AMO
treatment at REP decreased cardiac injury. Compared to untreated ISC-REP, AMO improved inner membrane potential in SSM
and IFM during REP, indicating preserved inner membrane integrity. Thus, direct pharmacologic modulation of electron trans-
port at REP protects mitochondria and decreases cardiac injury in the aged heart, even when signaling-induced pathways of post-
conditioning that are upstream of mitochondria are ineﬀective.
1. Introduction
The aged heart sustains increased injury during ischemia-
reperfusion in both experimental models [1–4] and in elderly
patients [5]. Aging hearts are also resistant to the powerful
endogenous protections provided by ischemic precondition-
ing and postconditioning [6–12]. Pharmacological condi-
tioning such as anesthetic preconditioning also does not pro-
tect the aging heart during ischemia-reperfusion [13]. Aging
causes dysfunction in interfibrillar mitochondria [14]. The
aging defect in complex III and cytochrome oxidase dec-
reases oxidative phosphorylation and increases the genera-
tion of reactive oxygen species [14–16]. Improvement of age-
inducedmitochondrial dysfunction with supplementation of
acetylcarnitine decreases myocardial injury during ischemia-
reperfusion [17], supporting that the electron transport
chain defects present in the aged heart contribute to the
increased myocardial injury.
Cardiac ischemia damages the electron transport chain
and leads to the increased generation of reactive oxygen spe-
cies (ROS) and mitochondrial calcium over load [18–22].
Opening of the mitochondrial permeability transition pore
(MPTP) is a critical step in the onset of cardiomyocyte death
[23, 24]. The increased generation of ROS and calcium over-
load are key factors that induce MPTP opening during cellu-
lar stress [25–28]. Although the increased production of ROS
and calcium overload occur during ischemia [18], MPTP
opening occurs mostly during reperfusion. Ischemia induces
intracellular acidification that blunts MPTP opening [25–
28]. Ischemic postconditioning decreases cardiac injury and
prevents MPTP opening in adult hearts [21], supporting that
MPTP mainly opens during reperfusion. Postconditioning
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leads to activation of cytoprotective signaling cascades,
including the reperfusion injury salvage kinase pathway cas-
cade (RISK) [29] and the tumor necrosis factor-STAT3
cascade (SAFE) [30]. Intervention during early reperfusion is
still able to reduce cardiac injury although ischemic damage
to the electron transport chain has already occurred [21, 31].
In fact, in the adult heart, postconditioning appears to work
via protection against MPTP in mitochondria that have sus-
tained damage from ischemia [32]. Unfortunately, ischemic
postconditioning does not protect aged myocardium [6, 33,
34]. Alternative approaches must be found to decrease car-
diac injury in the aged heart.
Blockade of electron transport with amobarbital dur-
ing ischemia protects cardiac mitochondria and decreases
myocardial injury in adult hearts [18, 19, 35]. Amobarbital
given before ischemia also decreases cardiac injury in aged rat
hearts measured after reperfusion [36]. These findings sug-
gest that direct manipulation of mitochondrial function is an
alternative approach to protect aged hearts that lack eﬀective
endogenous cytoprotective mechanisms.
Although prevention of mitochondrial damage during
ischemia by amobarbital treatment [18, 19, 35] or ischemic
preconditioning [6–8, 34] is an optimal strategy for cardio-
protection, the clinical relevance of these treatments is lim-
ited due to the unpredictable occurrence of ischemic events.
Interventions applied at the onset of reperfusion are practical
for therapeutic use in the treatment of acute myocardial
infarction [21, 37]. Direct blockade of electron transport by
amobarbital at the onset of reperfusion decreases myocardial
injury in the adult heart [19, 31]. In the present study, we
tested if blockade of electron transport at the onset of reper-
fusion was able to decrease cardiac injury in the aged heart.
We also evaluated if protection by direct modulation of mito-
chondrial function during early reperfusion is mediated by
the protection of mitochondrial inner membrane integrity.
2. Methods
2.1. Preparation of Rat Hearts for Perfusion. The Animal Care
and Use Committees of the McGuire VA Medical Center and
Virginia Commonwealth University approved the protocol.
Male Fischer rats (24 mo.) were anesthetized with pentobar-
bital sodium (100mg/kg i.p.) and anticoagulated with hepa-
rin (1000 IU/kg i.p.). Hearts were excised and perfused retro-
grade via the aorta in the Langendorﬀ mode with modified
Krebs-Henseleit (K-H) buﬀer oxygenated with 95% O2/5%
CO2 as previously described [35]. Cardiac function was
monitored with a balloon inserted into the left ventricle.
2.2. Protocol for Heart Ischemia and Reperfusion and Amobar-
bital Perfusion. In untreated hearts, the heart was perfused
for 15min with K-H buﬀer, followed by 25min global
ischemia at 37◦C and 30min reperfusion. In the amobarbital
treated group, hearts followed the same perfusion protocol
except that amobarbital (2.5mM) was perfused in identical
K-H buﬀer for three min at onset of reperfusion (Figure 1,
upper panel) [35]. Hearts were paced at 300 beats per min
during the 15min equilibration period and again after
10min reperfusion. Coronary eﬄuent was collected during
the 30min reperfusion period, and LDH activity in coronary
eﬄuent was determined to reflect myocardial injury [35].
2.3. Determination of Myocardial Infarct Size. In order to fur-
ther evaluate the amobarbital-mediated cardiac protection,
myocardial infarct size was measured in buﬀer-perfused
mouse hearts in the absence and presence of amobarbital
treatment at the onset of reperfusion. In untreated hearts, the
heart was perfused for 15min with K-H buﬀer, followed by
30min global ischemia at 37◦C and 60min reperfusion [38].
In the amobarbital-treated group, hearts followed the same
perfusion protocol except that amobarbital was perfused in
identical K-H buﬀer for three min at onset of reperfusion
(Figure 1, lower panel) [35]. Hearts were paced at 420 beats
per min during the 15min equilibration period and again
after 10min reperfusion. Coronary eﬄuent was collected
during the 30min reperfusion period, and LDH activity
in coronary eﬄuent was determined to reflect myocardial
injury [35]. Myocardial infarct size was determined using
TTC staining [35].
2.4. Mitochondrial Isolation and Functional Assessment. Sub-
sarcolemmal (SSM) and interfibrillar (IFM) mitochondria
were isolated from hearts at the end of the experiment [35].
Oxidative phosphorylation was determined using a Clark-
type oxygen electrode at 30◦C [35]. H2O2 production from
intact mitochondria was measured using the oxidation of the
fluorogenic indicator Amplex Red in the presence of horse-
radish peroxidase (HRP) [39].
2.5. Measurement of Mitochondrial Inner Membrane Potential.
Mitochondrial inner membrane potential was assessed using
the fluorescence intensity of the indicator TMRM (tetram-
ethylrhodamine, methyl ester) [40]. TMRM is a lipophilic
cation accumulated by mitochondria in proportion to Δψ
(emission at 590 nM, excitation at two wavelengths: 573 nm
and 546 nm). Accumulated TMRM in mitochondria causes a
fluorescence “red shift,” and fluorescence intensity was quan-
tified by calculating the ratio of intensity from 573 to inten-
sity from 546 (573/546). TMRMwas selected to reflect mem-
brane potential since TMRM did not inhibit oxidative phos-
phorylation at the concentration (0.3 μM) used [40]. The Δψ
was reflected by Δ change of fluorescence intensity of TMRM
in the presence of ADP (2mM), oligomycin (1 μM), and
DNP (0.2mM/each) using glutamate (10mM) as a complex
I substrate (Figure 4).
2.6. Determination of Calcium Tolerance Capacity (CRC).
Mitochondrial tolerance to calcium loading was studied in
the single-cell fluorometer using repetitive calcium pulses
[21, 41]. Freshly isolated SSM and IFM (0.2mg/mL) were
incubated in buﬀer (150mM sucrose, 50mM KCl, 2mM
KPi, and 20mM Tris/HCl, pH 7.4) for 90 sec. with stirring at
30◦C with 0.5 μM calcium green. Succinate (5mM) was used
as substrate. Pulses of calcium (20 nmoles) were added at
1min intervals. The number of pulses that resulted in
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Figure 1: Time course of ischemia and reperfusion. In the untreated rat heart group after 25min global ischemia, the heart underwent
30min reperfusion. In the amobarbital- (AMO-) treated group, the drug (2.5mM) was given for three min at the onset of reperfusion
followed by 27min of untreated Krebs-Henseleit buﬀer perfusion (upper panel). In isolated mouse hearts, hearts were subjected to 30min
global ischemia and 60min reperfusion with and without amobarbital treatment. The infarct size was determined at the end of reperfusion
(lower panel).
calcium release (MPTP opening) was used to calculate CRC
(Figure 6(a)).
2.7. Statistical Analysis. Data are expressed as the mean ±
standard error of the mean. Diﬀerences among groups were
compared by two-tailed t-test (SigmaStat 3.5, Program-
Paketet, Gothenburg, Sweden). Two-way ANOVA was used
to analyze the hemodynamic data and inner mitochondrial
membrane potential, and post hoc test was used to show
statistical diﬀerence between groups. A diﬀerence of P < 0.05
was considered significant.
3. Results
3.1. Reversible Blockade of Electron Transport at Onset of Re-
perfusion Decreased Myocardial Injury. There were no dif-
ferences in hemodynamic data (left ventricular developed
pressure-LVDP and left ventricular end diastolic pressure-
LVEDP) between the two groups at the end of the equilibra-
tion period before ischemia (Figure 2). Ischemia markedly
increased diastolic pressure (LVEDP) in both groups
(Figure 2). There was no diﬀerence in LVEDP between the
two groups at the end of ischemia, indicating that hearts in
both groups suﬀered the same degree of ischemic contracture
before treatment. The diastolic pressure remained elevated
during reperfusion in untreated hearts. Amobarbital given
during early reperfusion had minimal eﬀect on diastolic
pressure (Figure 2). In untreated hearts, LVDP is markedly
decreased during reperfusion compared to the preischemic
value. Amobarbital given during reperfusion tended to im-
prove the recovery of LVDP, but it did not reach statistical
significance (Figure 2). In contrast to cardiac function, amo-
barbital given at the onset of reperfusion markedly decreased
LDH release into coronary eﬄuent compared to untreated
hearts, indicating that modulation of electron transport
during early reperfusion provided solid cardioprotection in
aged hearts following reperfusion (Figure 3(a)). Amobar-
bital given during early reperfusion also protected buﬀer-
perfused mouse hearts as shown by decreased LDH release
(Figure 3(b)) andmyocardial infarct size (Figure 3(c)). These
data further support that reversible blockade of electron
transport during early reperfusion decreased myocardial
injury.
3.2. Reversible Blockade of Electron Transport at the Onset of
Reperfusion Did Not Improve Mitochondrial Oxidative Phos-
phorylation. Amobarbital given during reperfusion did not
improve oxidative phosphorylation in SSM or IFM (gluta-
mate, succinate, and TMPD-ascorbate as complex I, II, and
IV substrates, resp.) compared to untreated hearts (Table 1).
Amobarbital treatment also did not alter uncoupled respira-
tion induced by dinitrophenol (DNP) compared to untreated
hearts (Table 1). Thus, manipulation of respiration during
early reperfusion did not protect the electron transport
chain. This result was consistent with our previous findings
that the damage to the electron transport chain occurred
during ischemia, rather than during reperfusion [21, 35, 42].
3.3. Reversible Blockade of Electron Transport at the Onset of
Reperfusion Improved Mitochondrial Inner Membrane Poten-
tial. Mitochondrial inner membrane potential was used to
assess inner membrane permeability during reperfusion. An
original tracing of inner membrane potential is shown in
4 Journal of Aging Research
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Figure 2: Hemodynamic changes during ischemia and reperfusion.
There were no diﬀerences in left ventricular developed pressure
(LVDP) and diastolic pressure (LVEDP) between the two groups at
the end of the 15min equilibration (EQ) period before ischemia.
The diastolic pressure in untreated hearts was not diﬀerent in the
two groups at the end of ischemia, prior to treatment. LVDP and
LVEDP were similar in both groups during reperfusion. (Mean ±
SEM; ∗P < 0.05 versus preischemia value, n = 10 in each group.)
Figure 4. Mitochondrial inner membrane potential stimu-
lated by ADP was significantly improved in both SSM and
IFM by amobarbital treatment compared to untreated hearts
(Figure 5). Amobarbital treatment improved inner mem-
brane potential in the presence of oligomycin (complex V
inhibitor) in both SSM and IFM, suggesting that complex V
was not the site of the defect (Figure 5). Titration of DNP
caused complete depolarization of mitochondria (Figure 4).
Amobarbital treatment improved inner membrane potential
with DNP titration in both SSM and IFM (Figure 5).
3.4. Reversible Blockade of Electron Transport at Onset of
Reperfusion Did Not Improve Mitochondrial Calcium Reten-
tion Capacity (CRC). CRCwas used to assess MPTP opening
in isolated mitochondria [21]. An original tracing of CRC
measurement is shown in Figure 6(a). Amobarbital treat-
ment during reperfusion did not significantly improve CRC
in SSM and IFM compared to untreated hearts (Figure 6(b)).
3.5. Blockade of Electron Transport at the Onset of Reperfusion
Decreases H2O2 Generation. Mitochondrial electron trans-
port is a major source of ROS generation [22, 43]. Using
glutamate as a complex I substrate, amobarbital treatment
Table 1: Oxidative phosphorylation in SSM and IFM following
ischemia-reperfusion.
SSM IFM
ISC-REP AMO + REP ISC-REP AMO + REP
Glutamate-ADP 94± 10 109± 11 123± 11 145± 14
Glutamate-DNP 93± 9 114± 13 121± 12 149± 15
Succinate-ADP 100± 9 124± 10 127± 10 154± 13
Succinate-DNP 97± 9 119± 10 121± 10 148± 13
TMPD-ADP 408± 23 438± 16 488± 28 560± 36
Data are expressed as mean ± SEM; P = NS, ISC-REP versus AMO + REP,
N = 10 in each group.
decreased the generation of H2O2 in SSM compared to un-
treated hearts (Figure 7). The amount of H2O2 generated
from IFM from amobarbital treated hearts also was lower
than that in the untreated group (P = 0.051). There was
no diﬀerence in H2O2 production between the two groups
in both SSM and IFM using succinate + rotenone as a com-
plex II substrate (H2O2 pmol/mg/min Mean ± SEM: SSM,
109 ± 5 untreated versus 96 ± 9 amobarbital; IFM, 111 ±
3 untreated versus 114 ± 8 amobarbital, P = NS, n = 5 in
each group).
4. Discussion
The novel findings of the present study are (1) reversible
blockade of electron transport at the onset of reperfusion
decreases myocardial injury in aged hearts; (2) the protection
by amobarbital treatment during reperfusion was mediated
by protection of the inner mitochondrial membrane. The
present study indicates that modulation of mitochondrial
respiration at the onset of reperfusion is able to decrease car-
diac injury in the aged heart even when oxidative phospho-
rylation was already compromised from ischemia [42]. Thus,
the aged heart can be protected in a manner similar to the
adult heart by using this translationally relevant pharmaco-
logic strategy to attenuate cardiac injury during reperfusion.
Aging leads to impaired mitochondrial function that
augments myocardial injury during ischemia-reperfusion
[15, 17, 42]. The loss of endogenous protective mechanisms
in the aged heart provides a greater challenge to protect
the aged heart during acute myocardial infarction and its
treatment. The endogenous protective mechanisms can be
restored in aging hearts by treatments such as caloric restric-
tion [44], exercise [45], and a pharmacologic strategy to inhi-
bit protein phosphatase 2A activity [46]. Supplementation of
acetylcarnitine before ischemia decreases myocardial injury
in aged hearts via restoration of mitochondrial respiration to
an adult-phenotype [17]. However, these approaches must
all be instituted before ischemia and require variable pre-
treatment periods in order to be eﬀective. Due to the unpre-
dictable occurrence of acute ischemic events, these strate-
gies are unfortunately less clinically relevant to protect
the ischemic-reperfused aged heart. In the present study,
amobarbital given at the onset of reperfusion decreased
myocardial injury. Compared to the pre-ischemia strategies,
Journal of Aging Research 5
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Figure 3: LDH release during reperfusion in isolated rat hearts (a). LDH activity in coronary eﬄuent during 30min reperfusion was
measured in order to assess myocardial injury. Amobarbital given at the onset of reperfusion markedly decreased LDH release compared to
untreated hearts, supporting that the modulation of mitochondrial respiration during early reperfusion decreased myocardial injury in the
aged hearts. Amobarbital treatment also decreased LDH release in buﬀer perfused mouse hearts (b) and myocardial infarct size (c). (Mean±
SEM; ∗P < 0.05 versus untreated hearts n = 6–10 in each group.)
amobarbital treatment at reperfusion has therapeutic poten-
tial since amobarbital could be regionally infused during pri-
mary stent-mediated reperfusion treatment of ST elevation
acute infarcts in the high risk elderly patient population [5].
Amobarbital given before ischemia decreases cell injury
in isolated rabbit [19], rat [35, 47], and guinea pig hearts
[18]. Amobarbital given before ischemia prevents electron
transport chain damage measured following reperfusion in
isolated adult [35] and aged rat hearts [36]. In the present
study, amobarbital given at the onset of reperfusion does not
protect the electron transport chain in aged hearts. Taken
together, these results further support the notion that the
damage of mitochondrial electron transport chain mainly
occurs during ischemia, rather than during reperfusion [48],
including in the aged heart [49]. In the adult heart, amobar-
bital treatment during reperfusion decreases cardiac injury
without improving oxidative phosphorylation [31] indicat-
ing that the mechanism of myocyte death during reperfusion
is not solely dependent on the function of mitochondrial
respiration. Ischemic postconditioning, another well known
method applied during early reperfusion, also fails to im-
prove oxidative phosphorylation in the adult heart [21,
50]. Thus, manipulation of ischemia-damagedmitochondria
either via activation of cytoprotective signaling systems in the
adult heart [29, 50–52] or this novel direct manipulation of
mitochondrial function in the aged heart is able to decrease
myocardial injury during reperfusion.
MPTP opening contributes to myocyte death during
ischemia-reperfusion [23, 24, 53]. Although the exact struc-
ture of the MPTP remains elusive, the eﬀect of MPTP
opening is clear: its opening leads to increased permeability
of both mitochondrial inner and outer membranes [23, 26].
Mitochondrial inner membrane potential (Ψ) is commonly
used to reflect the permeability of the inner membrane [25,
53], including from MPTP. In the present study, inner mem-
brane potential was used to reflect inner membrane integrity
in isolated mitochondria. Amobarbital treatment preserves
inner membrane potential in both SSM and IFM compared
to untreated hearts, suggesting that amobarbital decreases
the permeability of inner membrane during reperfusion. In
the presence of oligomycin [54], inner membrane poten-
tial remains lower in mitochondria from untreated hearts
compared to amobarbital treatment, indicating that there
is a consistent proton leakage site other than complex V.
Ischemia-reperfusion may activate uncoupling proteins that
allow proton backflow into the matrix [54]. If this was the
case, we anticipate that the diﬀerence ofΨ between untreated
and amobarbital-treated mitochondria would be eliminated
in the presence of uncoupler, DNP. Amobarbital improves
innermembrane potential in the presence of DNP, suggesting
that uncoupling proteins are a less likely mechanism for
the proton leak. Another potential proton leak site is the
adenine nucleotide translocase (ANT) [54]. ANT was once
considered a key component of the MPTP, but the role of
ANT in the pore is now uncertain [55]. We found that inhi-
bition of ANT using bongkrekic acid did not restore inner
membrane potential in mitochondria following ischemia-
reperfusion (data not shown). These results indicate that the
impairment of inner membrane potential in mitochondria
isolated following ischemia-reperfusion in the aged heart is
not through the specific sites discussed above.
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Figure 4: Measurement of mitochondrial inner membrane poten-
tial. The upper panel is an original tracing of an inner membrane
potential measurement. Glutamate (10mM) was used as a com-
plex I substrate to polarize the inner membrane potential. ADP
stimulated the depolarization of inner membrane potential. Inner
membrane potential was restored when oligomycin was used to
inhibit complex V. Dinitrophenol (DNP) was titrated to completely
collapse inner membrane potential. The Δ change of fluorescence
intensity was used to assess inner mitochondrial membrane poten-
tial in the presence of ADP, oligomycin, and DNP. The lower panel
provides representative tracings of inner membrane potential from
mitochondria from untreated (blue line) and amobarbital-treated
(red line) hearts.
The improved inner membrane potential following amo-
barbital treatment suggests that treatment decreases MPTP
opening during reperfusion. However, amobarbital treat-
ment does not improve mitochondrial calcium tolerance
(calcium retention capacity—CRC), another common index
used to reflect MPTP [21, 56]. These results indicate that the
mechanism by which amobarbital treatment decreases inner
mitochondrial membrane permeability is not solely through
prevention of MPTP opening. Cardiolipin is a unique phos-
pholipid located in the inner membrane [48, 57, 58], and
insuﬃcient cardiolipin content or the presence of oxidized
cardiolipin increases inner membrane permeability [59, 60].
Aging does not alter cardiolipin content [61] but results in
the enhanced formation of oxidized cardiolipin species in
both SSM and IFM following ischemia compared to adult
hearts [49]. The increases in oxidized cardiolipin content
persist during reperfusion in the aged heart [49], sug-
gesting ongoing production during the oxidative stress
of reperfusion. Amobarbital treatment during reperfusion
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Figure 5: Mitochondrial inner membrane potential following
ischemia-reperfusion. Amobarbital treatment during reperfusion
improved inner mitochondrial potential measured following 30
minutes of reperfusion in both SSM (a) and IFM (b) in the presence
of ADP (ψ 1), oligomycin (ψ 2), and DNP (ψ 3). ψ 1–3 conditions
are as shown in Figure 4. (Mean± SEM; ∗P < 0.05 versus untreated
n = 10 in each group.)
may decrease the permeability of the inner membrane by
attenuating the ongoing production of oxidized cardiolipin
during reperfusion. This concept is an area of ongoing study
in our laboratory.
The burst of ROS formation at the onset of reperfu-
sion contributes to myocardial injury [22]. The ischemia-
damaged electron transport chain increases the generation
of ROS during reoxygenation in isolated mitochondria
[62]. Protection of mitochondrial electron transport during
ischemia decreases ROS generation during reperfusion [35,
36]. In the present study, amobarbital given during early
reperfusion decreases ROS generation from isolated mito-
chondria obtained from the aged heart, suggesting that amo-
barbital decreases myocardial injury by decreasing ROS for-
mation during reperfusion, perhaps leading to decreased
production of oxidized cardiolipin and thereby protecting
the inner mitochondrial membrane. Ischemia increases ROS
generation from complex I and complex III [62]. In the
present study, amobarbital treatment at the onset of reper-
fusion was likely protective by two complimentary mecha-
nisms. First, amobarbital decreased electron flow into com-
plex III, which produces increased oxidative injury from both
age-related [14–16] and ischemia-induced [35] defects, the
latter observed online in the intact heart [18]. Second, amo-
barbital treatment decreases complex-I-mediated complex I
damage [19, 35] with decreased production of ROS from
Journal of Aging Research 7
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Figure 6: Measurement of mitochondrial calcium tolerance. Succi-
nate (10mM) was used to energize mitochondria. The upper panel
(a) is an original tracing of calcium retention capacity (CRC). A
calcium pulse (20 nmoles) was added each time. The release of
calcium from mitochondria reflected opening of the permeability
transition pore. The lower panel (b) shows that amobarbital
treatment during reperfusion did not improve calcium tolerance in
SSM and IFM compared to mitochondria from untreated hearts.
(Mean ± SEM. P = NS versus untreated n = 10 in each group.)
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Figure 7: The generation of reactive oxygen species in mitochon-
dria following ischemia-reperfusion. Amobarbital treatment during
early reperfusion decreased net H2O2 production in subsarcolem-
mal mitochondria (SSM) compared to untreated hearts when gluta-
mate was used as a complex I substrate. Amobarbital also tended to
decrease net H2O2 production in interfibrillar mitochondria (IFM)
compared to untreated hearts (P < 0.06). Data are expressed as
mean ± SEM; ∗P < 0.05 versus untreated. N = 5 in each group.
complex I as observed during reperfusion in the current
study.
Reperfusion in clinical settings usually occurs following
at least moderate periods of ischemia that result in mito-
chondrial damage. Transient interruption of mitochondrial
oxidativemetabolism only during early reperfusion decreases
myocardial injury in aged hearts providing a relevant ap-
proach to limit myocardial cell death during reperfusion in
the high-risk elderly population.
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